Mustang Bio to Present at the Raymond James Human Health Innovation Conference
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Raymond James Human Health Innovation Virtual Conference
Stay informed and receive company updates straight to your inbox.